Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.

Atherosclerosis - 1 Sept 1999

Sunayama S, Watanabe Y, Ohmura H, Sawano M, Shimada K, Mokuno H, Daida H, Yamaguchi H

Abstract excerpt

Insulin resistance is associated with atherogenic lipoprotein phenotype, including small dense LDL particle, hypertriglycemia and low HDL cholesterol levels. Troglitazone, a novel insulin sensitizing agent, may improve the associated lipid profile in patients with insulin resistance. We examined the effects of troglitazone (400 mg daily for 12 weeks) in 12 non-diabetic coronary patients (60+/-10 years), all of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromans
Share to Glucose Tolerance Test
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoproteins, HDL

Share to Lipoproteins, LDL

Share to Probability

Share to Thiazoles

Share to Thiazolidinediones

Source

Identifiers

PMID: 10487503
DOI: 10.1016/s0021-9150(99)00138-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.PMID 10487503Read ↗

Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone.Semantic proximity Read ↗

Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.Semantic proximity Read ↗

Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?Semantic proximity Read ↗

Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.Semantic proximity Read ↗

Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes.Semantic proximity Read ↗

Angiographically-assessed coronary artery disease associates with HDL particle size in women.Semantic proximity Read ↗

The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.Semantic proximity Read ↗

Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease.Semantic proximity Read ↗

Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study.Semantic proximity Read ↗

Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia.Semantic proximity Read ↗

Lifestyle intervention improves lipoprotein particle size and distribution without weight loss in obese Latino adolescents.Semantic proximity Read ↗

Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.